Edgewise Therapeutics (EWTX) Return on Capital Employed (2021 - 2026)
Edgewise Therapeutics (EWTX) posted Return on Capital Employed of 38.9% for Q1 2026, down 9.88% sequentially from 35.4% in Q4 2025, and down 107.0% YoY from 555.71% in Q1 2025.
Edgewise Therapeutics (EWTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 38.9% in Q1 2026.
- Quarterly Return on Capital Employed fell 107.0% year-over-year to 38.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.9% (down 107.0% YoY) and the FY2025 annual result came in at 38.88%, up 189.0% from the prior year.
- Return on Capital Employed retreated to 38.9% in Q1 2026 per EWTX's latest filing, from 35.4% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 19.03% in Q1 2022 and troughed at 38.9% in Q1 2026.
- A 5-year average of 29.39% and a median of 29.28% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 1686 bps in 2023, then soared 438 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 20.15% in 2022, then sank by 84 bps to 37.02% in 2023, then grew by 10 bps to 33.42% in 2024, then decreased by 6 bps to 35.4% in 2025, then declined by 10 bps to 38.9% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 38.9%, 35.4%, and 31.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | -46.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.57% |
| Mar 31, 2026 | -38.90% |
| Dec 31, 2025 | -35.40% |
| Sep 30, 2025 | -31.38% |
| Jun 30, 2025 | -34.03% |
| Mar 31, 2025 | -37.83% |
| Dec 31, 2024 | -33.42% |
| Sep 30, 2024 | -29.28% |
| Jun 30, 2024 | -25.91% |
| Mar 31, 2024 | -28.55% |
| Dec 31, 2023 | -37.02% |
| Sep 30, 2023 | -33.67% |
| Jun 30, 2023 | -28.20% |
| Mar 31, 2023 | -23.99% |
| Dec 31, 2022 | -20.15% |
| Sep 30, 2022 | -20.53% |
| Jun 30, 2022 | -22.36% |
| Mar 31, 2022 | -19.03% |
| Dec 31, 2021 | -15.47% |
| Sep 30, 2021 | -12.66% |